To our knowledge, this is the first case reporting a pCR to neoadjuvant chemoimmunotherapy in a PPBC patient with ER+ErbB2-, MammaPrint high-risk, and BluePrint basal-type breast cancer as a personalized neoadjuvant treatment strategy. This evidence concerns the gene ERBB2 and breast cancer.